Skip to main content

Advertisement

Log in

Remission criteria and activity indices in psoriatic arthritis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Remission criteria and activity indices used in rheumatoid arthritis (RA) are often applied in psoriatic arthritis (PsA). Some new indices have been specifically developed for PsA. Our objective was to evaluate the performance of different remission criteria and activity indices in PsA. This is a cross-sectional study that includes consecutive patients with PsA. Information necessary to complete the following indices was captured: Composite Psoriatic Disease Activity Index (CPDAI), Psoriatic Arthritis Screening and Evaluation (PASE), Disease Activity Index for Psoriatic Arthritis (DAPSA), Disease Activity Score in 28 Joints (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), and American College of Rheumatology and European League Against Rheumatism (ACR/EULAR) Boolean RA remission criteria. Patients were classified according to activity categories (remission, low, medium, or high disease activity). Correlation between indices was established. Fifty-five patients were included. Mean age was 53 years (SD = 12), and 35 (63.6 %) were males. Mean PsA disease duration was 5.9 years (SD = 8.5), and mean psoriasis duration was 15.9 (SD = 12.6). We found important differences in the percentage of patients classified as in remission by applying different remission criteria: DAS28 = 33 % (95 % confidence interval (CI) 20–45) vs ACR/EULAR = 4 % (95 % CI 1–17). Particularly, DAS28 and minimal disease activity seemed to be less stringent in PsA than the other indices. Of the specific PsA indices evaluated, CPDAI showed the poorest correlation with all the other activity measurements, although differences were not statistically significant in most cases. Disease activity in PsA is measured by many different indices. In spite they all showed good correlations between them, they classified different patients in different disease status.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W (2004) Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 50(1):24–35. doi:10.1002/art.11417

    Article  PubMed  Google Scholar 

  2. Kavanaugh A, Cassell S (2005) The assessment of disease activity and outcomes in psoriatic arthritis. Clin Exp Rheumatol 23(5 Suppl 39):S142–S147

    CAS  PubMed  Google Scholar 

  3. Mease PJ, Antoni CE, Gladman DD, Taylor WJ (2005) Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 64(Suppl 2):ii49–ii54

    PubMed Central  PubMed  Google Scholar 

  4. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V et al (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38(6):727–735

    Article  CAS  PubMed  Google Scholar 

  5. van der Heijde DM, van’t Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, van Rijswijk MH, van de Putte LB (1990) Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 49(11):916–920

    Article  PubMed Central  PubMed  Google Scholar 

  6. Mumtaz A, Gallagher P, Kirby B, Waxman R, Coates LC, Veale JD, Helliwell P, FitzGerald O (2011) Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 70(2):272–277. doi:10.1136/ard.2010.129379

    Article  PubMed  Google Scholar 

  7. Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS (2010) Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 69(8):1441–1447. doi:10.1136/ard.2009.122259

    Article  PubMed  Google Scholar 

  8. Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, McHugh N, Mease PJ, Strand V, Waxman R, Azevedo VF, Beltran Ostos A, Carneiro S, Cauli A, Espinoza LR, Flynn JA, Hassan N, Healy P, Kerzberg EM, Lee YJ, Lubrano E, Marchesoni A, Marzo-Ortega H, Porru G, Moreta EG, Nash P, Raffayova H, Ranza R, Raychaudhuri SP, Roussou E, Scarpa R, Song YW, Soriano ER, Tak PP, Ujfalussy I, de Vlam K, Walsh JA (2013) The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 72(6):986–991. doi:10.1136/annrheumdis-2012-201341

    Article  PubMed  Google Scholar 

  9. Coates LC, Fransen J, Helliwell PS (2010) Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 69(1):48–53. doi:10.1136/ard.2008.102053

    Article  CAS  PubMed  Google Scholar 

  10. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, FitzGerald O, Aletaha D, Balint P, Boumpas D, Braun J, Breedveld FC, Burmester G, Canete JD, de Wit M, Dagfinrud H, de Vlam K, Dougados M, Helliwell P, Kavanaugh A, Kvien TK, Landewe R, Luger T, Maccarone M, McGonagle D, McHugh N, McInnes IB, Ritchlin C, Sieper J, Tak PP, Valesini G, Vencovsky J, Winthrop KL, Zink A, Emery P, European League Against R (2012) European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 71(1):4–12. doi:10.1136/annrheumdis-2011-200350

    Article  CAS  PubMed  Google Scholar 

  11. Lubrano E, Soriano E, FitzGerald O (2013) Can traditional disease-modifying anti-rheumatic drugs be withdrawn or tapered in psoriatic arthritis? Clin Exp Rheumatol 31(4 Suppl 78):S54–S58

    PubMed  Google Scholar 

  12. Gladman DD, Hing EN, Schentag CT, Cook RJ (2001) Remission in psoriatic arthritis. J Rheumatol 28(5):1045–1048

    CAS  PubMed  Google Scholar 

  13. Gladman DD, Chandran V, Thavaneswaran A, Zummer M (2012) Psoriatic arthritis in Canadian clinical practice: the PsA assessment in rheumatology. J Rheumatol 39(9):1850–1853. doi:10.3899/jrheum.120282

    Article  PubMed  Google Scholar 

  14. Cantini F, Niccoli L, Nannini C, Cassara E, Pasquetti P, Olivieri I, Salvarani C (2009) Criteria, frequency, and duration of clinical remission in psoriatic arthritis patients with peripheral involvement requiring second-line drugs. J Rheumatol Suppl 83:78–80. doi:10.3899/jrheum.090234

    Article  PubMed  Google Scholar 

  15. Cantini F, Niccoli L, Nannini C, Cassara E, Pasquetti P, Olivieri I, Salvarani C (2008) Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. Rheumatology 47(6):872–876. doi:10.1093/rheumatology/ken059

    Article  CAS  PubMed  Google Scholar 

  16. Theander E, Husmark T, Alenius GM, Larsson PT, Teleman A, Geijer M, Lindqvist UR (2013) Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis. doi:10.1136/annrheumdis-2012-201972

    Google Scholar 

  17. Lindqvist UR, Alenius GM, Husmark T, Theander E, Holmstrom G, Larsson PT, Psoriatic Arthritis Group of the Society for R (2008) The Swedish early psoriatic arthritis register—2-year followup: a comparison with early rheumatoid arthritis. J Rheumatol 35(4):668–673

    PubMed  Google Scholar 

  18. Kavanaugh A, Fransen J (2006) Defining remission in psoriatic arthritis. Clin Exp Rheumatol 24(6 Suppl 43):S083–S087

    Google Scholar 

  19. Caperon A, Helliwell PS (2012) Remission in psoriatic arthritis. J Rheumatol Suppl 89:19–21. doi:10.3899/jrheum.120235

    Article  PubMed  Google Scholar 

  20. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665–2673

    Article  PubMed  Google Scholar 

  21. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewe R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M, American College of R, European League Against R (2011) American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 63(3):573–586. doi:10.1002/art.30129

    Article  PubMed Central  PubMed  Google Scholar 

  22. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewe R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M (2011) American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70(3):404–413. doi:10.1136/ard.2011.149765

    Article  PubMed  Google Scholar 

  23. FitzGerald O, Helliwell P, Mease P, Mumtaz A, Coates L, Pedersen R, Nab H, Molta C (2012) Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set. Ann Rheum Dis 71(3):358–362. doi:10.1136/annrheumdis-2011-200093

    Article  PubMed  Google Scholar 

  24. Husni ME, Meyer KH, Cohen DS, Mody E, Qureshi AA (2007) The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol 57(4):581–587

    Article  PubMed  Google Scholar 

  25. Ferreyra Garrott LG, Soriano ER, Rosa JE, Navarta DA, Saucedo C, Scolnik M, Bedran Z, Sabelli M, Garcia MV, Anselmi C, Galimberti R, Catoggio LJ, Husni ME, Qureshi AA (2013) Validation in Spanish of a screening questionnaire for the detection of psoriatic arthritis in patients with psoriasis. Rheumatology 52(3):510–514. doi:10.1093/rheumatology/kes306

    Article  PubMed  Google Scholar 

  26. Dominguez PL, Husni ME, Holt EW, Tyler S, Qureshi AA (2009) Validity, reliability, and sensitivity-to-change properties of the psoriatic arthritis screening and evaluation questionnaire. Arch Dermatol Res 301(8):573–579. doi:10.1007/s00403-009-0981-3

    Article  PubMed Central  PubMed  Google Scholar 

  27. van Gestel AM, Prevoo ML, van’t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 39(1):34–40

    Article  PubMed  Google Scholar 

  28. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, van Riel PL, Tugwell P (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42(2):244–257

    Article  CAS  PubMed  Google Scholar 

  29. Citera G, Arriola MS, Maldonado-Cocco JA, Rosemffet MG, Sanchez MM, Goni MA, Spindler A, Lucero E, Berman A (2004) Validation and crosscultural adaptation of an argentine spanish version of the health assessment questionnaire disability index. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis 10(3):110–115. doi:10.1097/01.rhu.0000128732.58292.cd

    Google Scholar 

  30. Coates LC, Fitzgerald O, Mease PJ, Gladman DD, Strand V, Goel N, Campbell I, Krueger G, McHugh NJ, Helliwell PS (2014) Development of a Disease Activity and Responder Index for Psoriatic Arthritis—report of the psoriatic arthritis module at OMERACT 11. J Rheumatol 41:782–791. doi:10.3899/jrheum.131250

    Article  PubMed  Google Scholar 

  31. Coates LC, Navarro-Coy N, Brown SR, Brown S, McParland L, Collier H, Skinner E, Law J, Moverley A, Pavitt S, Hulme C, Emery P, Conaghan PG, Helliwell PS (2013) The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet Disord 14:101. doi:10.1186/1471-2474-14-101

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare no conflict of interests.

Funding

There was no funding for this study.

Ethical approval

The study was conducted according to the Declaration of Helsinki and local regulations. Ethical approval for the study was obtained from the hospital local ethics committee, and informed consent was obtained from all patients.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to E. R. Soriano.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Acosta Felquer, M.L., Ferreyra Garrott, L., Marin, J. et al. Remission criteria and activity indices in psoriatic arthritis. Clin Rheumatol 33, 1323–1330 (2014). https://doi.org/10.1007/s10067-014-2626-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-014-2626-y

Keywords

Navigation